Table 2 Adverse events
|  | All (N = 83) (%) | No ascites (N = 43) (%) | Small to moderate ascites (N = 26) (%) | Massive ascites (N = 14) (%) | P valuea | ||||
|---|---|---|---|---|---|---|---|---|---|
All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | ||
Hematological toxicity | |||||||||
 Any | 70 (84) | 52 (63) | 35 (81) | 22 (51) | 24 (92) | 20 (77) | 11 (79) | 10 (71) | 0.076 |
 Neutropenia | 61 (73) | 40 (48) | 30 (70) | 19 (44) | 21 (81) | 19 (73) | 10 (71) | 8 (57) | 0.064 |
 Leukopenia | 59 (71) | 32 (39) | 29 (67) | 11 (26) | 20 (77) | 14 (54) | 10 (71) | 7 (50) | 0.041 |
 Anemia | 27 (33) | 8 (10) | 15 (35) | 4 (9) | 9 (35) | 3 (12) | 3 (21) | 1 (7) | 0.49 |
 Thrombocytopenia | 8 (10) | 3 (4) | 4 (9) | 3 (7) | 3 (12) | 0 | 1 (7) | 0 | 0.72 |
Nonhematological toxicity | |||||||||
 Any | 76 (92) | 10 (12) | 39 (91) | 4 (9) | 24 (92) | 4 (15) | 13 (93) | 2 (14) | 0.72 |
 Fatigue | 38 (46) | 0 | 20 (47) | 0 | 9 (35) | 0 | 9 (64) | 0 | 0.23b |
 Neuropathy | 38 (46) | 0 | 23 (53) | 0 | 11 (42) | 0 | 6 (43) | 0 | 0.87b |
 Anorexia | 37 (45) | 6 (7) | 17 (40) | 2 (5) | 12 (46) | 3 (12) | 8 (57) | 1 (7) | 0.56 |
 Hypertention | 24 (29) | 2 (2) | 11 (26) | 0 | 10 (38) | 1 (4) | 3 (21) | 1 (7) | 0.27 |
 Peripheral edema | 23 (28) | 0 | 11 (26) | 0 | 7 (27) | 0 | 5 (36) | 0 | 0.74b |
 Proteinuria | 9 (11) | 0 | 4 (9) | 0 | 5 (19) | 0 | 0 | 0 | 0.12b |
 Diarrhea | 8 (10) | 0 | 6 (14) | 0 | 1 (4) | 0 | 1 (7) | 0 | 0.36b |
 Epistaxis | 8 (10) | 0 | 5 (12) | 0 | 1 (4) | 0 | 2 (14) | 0 | 0.62b |
 Febrile netropenia | 3 (4) | 3 (4) | 3 (7) | 3 (7) | 0 | 0 | 0 | 0 | 0.26 |